{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:48:44Z","timestamp":1758808124793,"version":"3.44.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ucl.2012.07.009","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T00:18:37Z","timestamp":1346717917000},"page":"533-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bone-Targeted Agents"],"prefix":"10.1016","volume":"39","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4861","key":"10.1016\/j.ucl.2012.07.009_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.3388021","article-title":"Evidence of estrogen receptors in normal human osteoblast-like cells","volume":"241","author":"Eriksen","year":"1988","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2012.07.009_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.009_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2012.07.009_bib4","first-page":"1248","article-title":"Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline","volume":"164","author":"Berruti","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2012.07.009_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000474311","article-title":"Osteoblast function and osteomalacia in metastatic prostate cancer","volume":"24","author":"Clarke","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2012.07.009_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","article-title":"Monomorphic evidence for bone resorption and replacement in prostate cancer","volume":"68","author":"Clarke","year":"1991","journal-title":"Br J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.009_bib7","first-page":"18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.009_bib8","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1158\/1078-0432.CCR-03-0735","article-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer","volume":"10","author":"Micahelson","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.009_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ucl.2012.07.009_bib10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.009_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V83.4.958.958","article-title":"Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults","volume":"83","author":"Kahn","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ucl.2012.07.009_bib12","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1016\/S0021-9258(18)67143-1","article-title":"Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-Sepharose","volume":"261","author":"Hauschka","year":"1986","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ucl.2012.07.009_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ucl.2012.07.009_bib14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.ucl.2012.07.009_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.009_bib16","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.009_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.ucl.2012.07.009_bib18","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with non-metastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.009_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ucl.2012.07.009_bib20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ucl.2012.07.009_bib21","first-page":"3431","article-title":"Osteoporosis in men","volume":"84","author":"Bilezikian","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ucl.2012.07.009_bib22","first-page":"2361","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.009_bib23","first-page":"181","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.009_bib24","first-page":"1219","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.009_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5694\/j.1326-5377.1997.tb126646.x","article-title":"Hip fracture in elderly men: prognostic factors and outcomes","volume":"167","author":"Diamond","year":"1997","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.009_bib26","first-page":"136","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2012.07.009_bib27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1172\/JCI119701","article-title":"Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens","volume":"100","author":"Slemenda","year":"1997","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.ucl.2012.07.009_bib28","first-page":"2266","article-title":"Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen","volume":"83","author":"Khosla","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ucl.2012.07.009_bib29","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1359\/jbmr.1997.12.11.1833","article-title":"Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study","volume":"12","author":"Greendale","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.009_bib30","first-page":"511","article-title":"Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men","volume":"86","author":"Leder","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2012.07.009_bib31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.009_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bone.2010.05.038","article-title":"Treatment and prevention of bone complications from prostate cancer","volume":"48","author":"Lee","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ucl.2012.07.009_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"The myeloma Aredia Study G. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.009_bib34","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"The Protocol 19 Aredia Breast Cancer Study G. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyl","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.009_bib35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.009_bib36","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.009_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CGC.2010.n.005","article-title":"Contemporary therapeutic approaches targeting bone complications in prostate cancer","volume":"8","author":"Lee","year":"2010","journal-title":"Clin Genitourin Cancer"},{"issue":"9768","key":"10.1016\/j.ucl.2012.07.009_bib38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.009_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.009_bib40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.009_bib41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.ucl.2012.07.009_bib42","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.009_bib43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.009_bib44","first-page":"152","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2012.07.009_bib45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ucl.2012.07.009_bib46","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men\u00a0with prostate carcinoma receiving combined androgen blockade","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.009_bib47","first-page":"2008","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2012.07.009_bib48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib49","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/JBMR.040813","article-title":"Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer","volume":"19","author":"Morabito","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ucl.2012.07.009_bib50","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00198-006-0160-8","article-title":"Bone fragility in men\u2014where are we?","volume":"17","author":"Seeman","year":"2006","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.009_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.009_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jocd.2008.04.003","article-title":"National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist","volume":"11","author":"Watts","year":"2008","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.ucl.2012.07.009_bib53","first-page":"2200","article-title":"Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer","volume":"183","author":"Saylor","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2012.07.009_bib54","first-page":"2670","article-title":"Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"182","author":"Smith","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2012.07.009_bib55","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2012.07.009_bib56","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2012.07.009_bib57","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined\u00a0analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib58","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib59","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A\u00a0double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2012.07.009_bib60","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib61","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer\u2014results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2012.07.009_bib62","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib63","unstructured":"Wirth M, Tammela T, DeBruyne F, et\u00a0al. Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients. A randomised, open label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). A report of the ZEUS study. 2008 Genitourinary Cancers Symposium [abstract no: 184]. Genitourinary Cancer Symposium. American Society of Clinical Oncology. San Francisco, February 14\u201316, 2008."},{"issue":"9810","key":"10.1016\/j.ucl.2012.07.009_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2012.07.009_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A\u00a0comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib66","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2012.07.009_bib67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2012.07.009_bib68","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","article-title":"Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial","volume":"16","author":"Serafini","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.009_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2012.07.009_bib70","first-page":"1451","article-title":"Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer","volume":"33","author":"Farhanghi","year":"1992","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ucl.2012.07.009_bib71","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<620::AID-CNCR19>3.0.CO;2-#","article-title":"Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate","volume":"88","author":"Kossman","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.009_bib72","unstructured":"Parker C, Heinrich D, O'Sullivan JM, et\u00a0al. Overall survival\u00a0benefit and safety profile of radium-223 chloride, a first-in- class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract: 8]. Oral Abstract Session A."}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014312000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014312000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:25:04Z","timestamp":1758806704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014312000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0094014312000572"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2012.07.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone-Targeted Agents","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2012.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}